17.18 USD
+0.32 (+1.9%)
Overall PHAR gets a fundamental rating of 6 out of 10. We evaluated PHAR against 530 industry peers in the Biotechnology industry. PHAR is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PHAR has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PHAR had negative earnings in the past year.
PHAR had a positive operating cash flow in the past year.
In multiple years PHAR reported negative net income over the last 5 years.
In multiple years PHAR reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.02%, PHAR belongs to the top of the industry, outperforming 88.49% of the companies in the same industry.
PHAR has a Return On Equity of 0.04%. This is amongst the best in the industry. PHAR outperforms 90.00% of its industry peers.
PHAR has a Return On Invested Capital of 7.52%. This is amongst the best in the industry. PHAR outperforms 93.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | 7.52% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHAR has a Profit Margin of 0.03%. This is amongst the best in the industry. PHAR outperforms 88.68% of its industry peers.
PHAR has a better Operating Margin (10.15%) than 91.70% of its industry peers.
The Gross Margin of PHAR (89.90%) is better than 92.26% of its industry peers.
PHAR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
PHAR has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, PHAR has more shares outstanding
The number of shares outstanding for PHAR has been increased compared to 5 years ago.
The debt/assets ratio for PHAR has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.14 indicates that PHAR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.14, PHAR is in the better half of the industry, outperforming 71.13% of the companies in the same industry.
PHAR has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHAR would need 2.49 years to pay back of all of its debts.
The Debt to FCF ratio of PHAR (2.49) is better than 93.58% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that PHAR is not too dependend on debt financing.
PHAR has a worse Debt to Equity ratio (0.46) than 70.00% of its industry peers.
Although PHAR does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 4.14 |
ROIC/WACC1.08
WACC6.97%
2.3 Liquidity
PHAR has a Current Ratio of 3.16. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
PHAR's Current ratio of 3.16 is on the low side compared to the rest of the industry. PHAR is outperformed by 62.45% of its industry peers.
PHAR has a Quick Ratio of 2.40. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
PHAR has a Quick ratio of 2.40. This is in the lower half of the industry: PHAR underperforms 69.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
PHAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
The Revenue has grown by 26.78% in the past year. This is a very strong growth!
The Revenue has been growing by 10.64% on average over the past years. This is quite good.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
PHAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.48% yearly.
Based on estimates for the next years, PHAR will show a quite strong growth in Revenue. The Revenue will grow by 8.97% on average per year.
EPS Next Y234.87%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PHAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
PHAR is valuated quite expensively with a Price/Forward Earnings ratio of 59.66.
PHAR's Price/Forward Earnings ratio is rather cheap when compared to the industry. PHAR is cheaper than 90.00% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.57. PHAR is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.66 |
4.2 Price Multiples
93.77% of the companies in the same industry are more expensive than PHAR, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, PHAR is valued cheaper than 95.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.39 | ||
| EV/EBITDA | 21.14 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PHAR may justify a higher PE ratio.
PHAR's earnings are expected to grow with 59.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.54%
EPS Next 3Y59.38%
5. Dividend
5.1 Amount
No dividends for PHAR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PHAR (1/7/2026, 8:00:01 PM)
17.18
+0.32 (+1.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners21.51%
Inst Owner Change0%
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap1.18B
Revenue(TTM)362.27M
Net Income(TTM)100.00K
Analysts88.57
Price Target17.73 (3.2%)
Short Float %0.04%
Short Ratio1.33
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.19%
PT rev (3m)-16.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)201.53%
EPS NY rev (1m)-27.9%
EPS NY rev (3m)-52.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.7%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)6.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 59.66 | ||
| P/S | 3.25 | ||
| P/FCF | 22.39 | ||
| P/OCF | 22.13 | ||
| P/B | 4.44 | ||
| P/tB | 9.05 | ||
| EV/EBITDA | 21.14 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.29
Fwd EY1.68%
FCF(TTM)0.77
FCFY4.47%
OCF(TTM)0.78
OCFY4.52%
SpS5.29
BVpS3.87
TBVpS1.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | 9.52% | ||
| ROIC | 7.52% | ||
| ROICexc | 13.21% | ||
| ROICexgc | 34.23% | ||
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% | ||
| FCFM | 14.51% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 4.03% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 6 | ||
| Cash Conversion | 101.53% | ||
| Profit Quality | 52570% | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | 4.14 |
F-Score7
WACC6.97%
ROIC/WACC1.08
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y234.87%
EPS Next 2Y104.54%
EPS Next 3Y59.38%
EPS Next 5Y53.48%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year26.31%
Revenue Next 2Y14.87%
Revenue Next 3Y10.89%
Revenue Next 5Y8.97%
EBIT growth 1Y357.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV - ADR / PHAR FAQ
Can you provide the ChartMill fundamental rating for PHARMING GROUP NV - ADR?
ChartMill assigns a fundamental rating of 6 / 10 to PHAR.
What is the valuation status for PHAR stock?
ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV - ADR (PHAR). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV - ADR?
PHARMING GROUP NV - ADR (PHAR) has a profitability rating of 6 / 10.
Can you provide the financial health for PHAR stock?
The financial health rating of PHARMING GROUP NV - ADR (PHAR) is 7 / 10.